First FDA Approval of Combined Immunotherapy Treatment for NSCLC
On May 15, 2020, the Food and Drug Administration (FDA) approved the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) for treatment of advanced non-small cell lung cancer (NSCLC) with a PD-L1 level equal to or greater than 1% for [...]